Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Theralase Technologies Inc. > Herpes
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(374)
•••
Comment by CancerSlayeron Jun 13, 2024 6:02pm
151 Views
Post# 36088134

RE:RE:RE:RE:RE:Herpes

RE:RE:RE:RE:RE:Herpes
patience69 wrote: There are currently no products otc or  which kill the virus. They just slow it. That is for herpes simplex or genital. I would be shocked if glaxo was not all over this. Let them develop it for cash up front and a royalty 



I think the big benefit derived from our preclinical antiviral tech can be found in any potential for vaccine development.  A topical may improve symptoms & shorten their duration a bit, however, it doesn't prevent or immediately heal lesions.  

As far as I'm aware, there are currently no licensed prophylactic or therapeutic vaccines available on the market today against the Herpes Simplex Virus (HSV).  An effective & perhaps less expensive topical alternative sounds good, but the potential for a promising antiviral vaccine platform as well as topical sounds a lot better to me.  JMO.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities